Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20117898 | 0.81 | HPGD (0.39) | FFAR1SLC6A4HTR6 | |
| SCHEMBL26770383 | 0.81 | HTR2A (0.44) | FFAR1SLC6A4HTR6PARP10MCHR1 | |
| SCHEMBL16501544 | 0.81 | SLC6A4 (0.47) | SLC6A4HTR6PARP10MCHR1PARP15 | |
| SCHEMBL20102467 | 0.80 | PTGDR2 (0.37) | FFAR1SLC6A4HTR6 | |
| SCHEMBL26770373 | 0.78 | HTR2C (0.44) | FFAR1SLC6A4HTR6PARP10ALOX5AP | |
| SCHEMBL18466652 | 0.78 | MCHR1 (0.50) | SLC6A4PARP10MCHR1 | |
| SCHEMBL26505542 | 0.76 | SLC6A4 (0.39) | FFAR1SLC6A4HTR6PARP10MCHR1 | |
| SCHEMBL1500529 | 0.76 | SLC6A4 (0.43) | FFAR1SLC6A4HTR6PARP10MCHR1 | |
| SCHEMBL20111289 | 0.76 | SLC6A4 (0.35) | SLC6A4HTR6PARP10ALOX5APFEN1 | |
| SCHEMBL26770363 | 0.75 | HTR2C (0.47) | PARP10PARP15HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | FFAR1 536/4885SLC6A4 2219/4885HTR6 2692/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | FFAR1 536/4885SLC6A4 2219/4885HTR6 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.